Detalhe da pesquisa
1.
Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study.
Euro Surveill
; 29(15)2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38606569
2.
Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-ß-Lactamase VIM-1.
Antimicrob Agents Chemother
; 67(5): e0150522, 2023 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195077
3.
Simultaneous and divergent evolution of resistance to cephalosporin/ß-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
J Antimicrob Chemother
; 78(5): 1195-1200, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918743
4.
Kpi, a chaperone-usher pili system associated with the worldwide-disseminated high-risk clone Klebsiella pneumoniae ST-15.
Proc Natl Acad Sci U S A
; 117(29): 17249-17259, 2020 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32641516
5.
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel ß-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales.
Antimicrob Agents Chemother
; 66(2): e0167621, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807754
6.
Selection of AmpC ß-Lactamase Variants and Metallo-ß-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Antimicrob Agents Chemother
; 66(2): e0206721, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930034
7.
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother
; 77(10): 2809-2815, 2022 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35904000
8.
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
J Antimicrob Chemother
; 76(1): 91-100, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33083833
9.
Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales.
J Antimicrob Chemother
; 76(6): 1498-1510, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33677560
10.
Antisense inhibition of lpxB gene expression in Acinetobacter baumannii by peptide-PNA conjugates and synergy with colistin.
J Antimicrob Chemother
; 75(1): 51-59, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31586411
11.
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
J Antimicrob Chemother
; 75(11): 3209-3217, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728723
12.
In Vitro and In Vivo Assessment of the Efficacy of Bromoageliferin, an Alkaloid Isolated from the Sponge Agelas dilatata, against Pseudomonas aeruginosa.
Mar Drugs
; 18(6)2020 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32585891
13.
Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds.
Mar Drugs
; 18(7)2020 Jul 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32708418
14.
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Antimicrob Agents Chemother
; 63(10)2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383659
15.
Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii.
Antimicrob Agents Chemother
; 63(10)2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383666
16.
Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum ß-Lactamase-Producing Enterobacterales".
Antimicrob Agents Chemother
; 66(5): e0035322, 2022 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35471039
17.
Activity of the ß-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D ß-Lactamases from Acinetobacter baumannii.
Antimicrob Agents Chemother
; 61(11)2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807908
18.
Activity of cefiderocol and innovative ß-lactam/ß-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double ß-lactamases under high and low permeability conditions.
Int J Antimicrob Agents
; 63(5): 107150, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513748
19.
Activity of aztreonam in combination with novel ß-lactamase inhibitors against metallo-ß-lactamase-producing Enterobacterales from Spain.
Int J Antimicrob Agents
; 61(4): 106738, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36736925
20.
Development of a novel streamlined workflow (AACRE) and database (inCREDBle) for genomic analysis of carbapenem-resistant Enterobacterales.
Microb Genom
; 9(11)2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010338